Understanding Viral Hemorrhagic Fever Risks: Ebola and Marburg Viruses

The World Health Organization (WHO) and regional health authorities maintain heightened surveillance for viral hemorrhagic fevers following confirmed cases of Ebola and Marburg virus disease in East Africa. While both pathogens cause severe illness characterized by high fever and internal bleeding, they are distinct viruses that require specific diagnostic testing and public health interventions to contain transmission and prevent regional outbreaks.

How do Ebola and Marburg viruses differ?

Although Ebola and Marburg viruses belong to the same family, Filoviridae, they are caused by different viral species. According to the World Health Organization, Ebola virus disease (EVD) is caused by several species within the Ebolavirus genus, whereas Marburg virus disease (MVD) is caused by the Marburg marburgvirus.

Both viruses are zoonotic, meaning they jump from animals to humans. Fruit bats are considered natural reservoirs for both pathogens. Clinically, both diseases present with similar symptoms, including high fever, headache, muscle pain, and eventually, severe hemorrhaging. Because the clinical presentation is nearly identical, healthcare providers rely on laboratory confirmation—typically through Reverse Transcription Polymerase Chain Reaction (RT-PCR) testing—to distinguish between the two.

What is the current status of the outbreak?

Public health response efforts are currently focused on containment and contact tracing in affected regions. Official reports from the WHO Disease Outbreak News confirm that when cases of either virus are identified, immediate quarantine protocols are initiated to break the chain of human-to-human transmission.

Transmission occurs through direct contact with the blood, secretions, organs, or other bodily fluids of infected people, or with surfaces and materials contaminated with these fluids. Unlike respiratory viruses such as influenza or SARS-CoV-2, these filoviruses are not airborne. Containment strategies emphasize the use of personal protective equipment (PPE) for healthcare workers and the implementation of safe, dignified burial practices to prevent contact with the bodies of the deceased, which remain highly infectious.

How do health agencies manage cross-border risks?

International health agencies coordinate with local ministries of health to manage the risk of viral spread. Surveillance systems at border crossings and major transportation hubs are often enhanced during outbreaks. According to the U.S. Embassy in Uganda, travelers in affected regions are advised to monitor official health alerts, avoid contact with wildlife, and seek immediate medical attention if they develop symptoms consistent with hemorrhagic fever.

The primary challenge in managing these outbreaks is the rapid identification of cases in remote areas. Early detection remains the most effective tool to prevent a localized cluster from becoming a widespread epidemic.

Key Facts About Viral Hemorrhagic Fevers

• Pathogen Family: Both are Filoviridae.
• Primary Reservoir: Fruit bats (Pteropodidae family).
• Transmission: Direct contact with infected bodily fluids; not airborne.
• Diagnosis: Confirmed via RT-PCR laboratory testing.
• Prevention: Strict infection control, PPE, and safe burial practices.

What should the public know about pandemic risk?

While the emergence of these viruses causes significant local concern, the high case-fatality rates—which can reach up to 90% for some strains—often act as a natural limiting factor for widespread transmission. Because the disease progresses quickly and is physically debilitating, infected individuals are less likely to travel extensively, which helps limit the virus’s ability to move rapidly across global populations compared to more transmissible respiratory pathogens.

Ongoing research into vaccines and therapeutics continues to evolve. Several candidate vaccines for Ebola have been deployed in recent years, while research for Marburg-specific medical countermeasures remains a global health priority. Preventing future outbreaks depends on continued investment in local surveillance infrastructure and the rapid deployment of resources to the point of origin.